The How: Current Predictors of Response to Immune Checkpoint Inhibitors

Download this slideset to review expert guidance on optimal biomarker testing in lung cancer, including molecular testing by NGS and PD-L1 testing to predict response to checkpoint inhibitor–based therapy.
Sanjay Mukhopadhyay, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 4.71 MB
Released: November 5, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Genentech
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: August 17, 2022

Population-based assessment of the association between socioeconomic deprivation and utilization of novel therapies in patients with NSCLC from the United Kingdom, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 17, 2022

Prespecified interim analysis of OS from phase III IMpower010 trial of adjuvant atezolizumab in early-stage NSCLC, presented at WCLC 2022 and reported by Clinical Care Options (CCO)

Released: August 16, 2022

Cohort from phase Ib CodeBreaK100/101 studies of sotorasib + atezolizumab or pembrolizumab in KRAS G12C-mutated NSCLC, presented at WCLC 2022 as reported by Clinical Care Options (CCO)

Released: August 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings